Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14228809 | 0.87 | ATM (0.44) | ATMSMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL5874399 | 0.85 | L3MBTL1 (0.39) | ATMSMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL5874669 | 0.85 | ATM (0.43) | ATMSMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL442464 | 0.83 | L3MBTL1 (0.38) | ATMSMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL5874140 | 0.81 | ALDH1A1 (0.38) | ATMSMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL28413576 | 0.80 | L3MBTL1 (0.46) | SMN1; SMN2MAPK1 | |
| SCHEMBL8430106 | 0.78 | L3MBTL1 (0.53) | MAPK1 | |
| SCHEMBL3770358 | 0.78 | L3MBTL1 (0.47) | ATMSMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL5874880 | 0.78 | L3MBTL1 (0.47) | CYP1A2MAPK1 | |
| SCHEMBL8431983 | 0.77 | L3MBTL1 (0.52) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578265-B2 | AIEgens for cancer cell imaging | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2023-02-14 | — | — | US | disclosed |
| US-20210371735-A1 | AIEgens for Cancer Cell Imaging | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578265-B2 | AIEgens for cancer cell imaging | CD4, MKI67, CCNB1 | ATM 2694/4885SMN1; SMN2 4476/4885CYP1A2 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.